How certain liver proteins are regulated by chemical modifications

Regulation of OATP1B1 and OATP1B3 by lysine acetylation and lysine deacetylase inhibitors

NIH-funded research University of Oklahoma Hlth Sciences Ctr · NIH-10873782

This study is looking at how certain liver proteins that help move medications into the liver are controlled, which could help doctors better understand how different drugs work together and their possible side effects, especially for people who take several medications.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Oklahoma Hlth Sciences Ctr NIH-funded
Lab location1 site (Oklahoma City, United States)
Project IDNIH-10873782 on NIH RePORTER

What this research studies

This research investigates how specific liver proteins, known as OATP1B1 and OATP1B3, are regulated by a process called lysine acetylation. These proteins play a crucial role in transporting various drugs and toxins into the liver, which can affect how medications work and their potential side effects. By understanding the molecular mechanisms that control these proteins, the research aims to improve predictions of drug interactions and adverse effects, particularly for patients taking multiple medications. The study will involve laboratory experiments to explore how changes in acetylation influence the function of these transport proteins.

Who could benefit from this research

Good fit: Ideal candidates for this research include patients who are taking multiple medications, especially those involving statins or anticancer agents.

Not a fit: Patients who are not on any medications or those with conditions unrelated to drug metabolism may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to safer medication use by reducing the risk of adverse drug interactions.

How similar studies have performed: Previous research has shown that understanding the regulation of drug transport proteins can lead to significant advancements in predicting drug interactions, suggesting this approach has potential for success.

Where this research is happening

Oklahoma City, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer Agents
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.